Celiprolol and sympatho-immune interface in COVID-19
Immunology
.
2023 Dec;170(4):579-582.
doi: 10.1111/imm.13693.
Epub 2023 Sep 7.
Authors
Hayder M Al-Kuraishy
1
,
Ali K Albuhadily
1
,
Ali I Al-Gareeb
1
,
Maisra M El-Bouseary
2
,
Athanasios Alexiou
3
4
,
Marios Papadakis
5
,
Gaber El-Saber Batiha
6
Affiliations
1
Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.
2
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
3
Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.
4
AFNP Med, Wien, Austria.
5
Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany.
6
Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, Egypt.
PMID:
37679864
DOI:
10.1111/imm.13693
No abstract available
Publication types
Letter
MeSH terms
COVID-19*
Celiprolol*
Humans
Substances
Celiprolol